GlassScriptPhysician profile
Tehilla Apfel
NPI 1396163341
$2,966.36
in general payments reported to CMS, 2019-2025
22 companies · $706 in 2025
The $706 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $319 · 2022: $611 · 2023: $618 · 2024: $712 · 2025: $706.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,036.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,036.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $887.94 | 2021-2025 | Skyrizi, Rinvoq, Mavyret |
| Janssen Biotech, INC. | $403.36 | 2021-2025 | Stelara, Simponi, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $360.54 | 2021-2024 | Xifaxan |
| Gilead Sciences, INC. | $192.68 | 2023-2025 | |
| Ardelyx, INC. | $164.38 | 2023-2025 | Ibsrela |
| Celgene Corporation | $150.77 | 2021-2024 | Zeposia |
| Madrigal Pharmaceuticals | $128.06 | 2025 | Rezdiffra |
| Pfizer INC. | $113.35 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $100.96 | 2023-2025 | Entyvio, Gattex, Eohilia |
| E.R. Squibb & Sons, L.L.C. | $99.48 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $55.88 | 2024-2025 | Dupixent |
| Phathom Pharmaceuticals, INC. | $44.73 | 2025 | Voquezna |
| Braintree Laboratories, INC. | $43.44 | 2021 | |
| Lilly USA, LLC | $43.23 | 2025 | Omvoh |
| Merck Sharp & Dohme LLC | $39.99 | 2021-2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $25.22 | 2025 | Tremfya |
| Redhill Biopharma INC. | $23.69 | 2023 | Talicia |
| Celltrion USA INC. | $22.75 | 2024 | Vegzelma |
| Aimmune Therapeutics, INC. | $18.83 | 2025 | Zenpep |
| Qol Medical, LLC | $16.51 | 2023 | Sucraid |
| Mauna Kea Technologies, INC. | $16.11 | 2021 | |
| Novo Nordisk INC | $14.46 | 2023 | Wegovy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tehilla Apfel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.